Hevylite^®

Use Hevylite to accurately and quantitatively monitor intact immunoglobulin Multiple Myeloma patients when electrophoresis is inaccurate or insensitive. This laboratory test overcomes technical issues seen with SPE/CZE/IFE such as co-migration, fuzzy/diffuse bands and dye saturation. More accurate information improves patient care.

• Equivalence to current methods like SPE and IFE has been shown, with almost perfect agreement, for patient responses following treatment
• In studies monitoring IgA Multiple Myeloma, monoclonality was detected by an abnormal Hevylite ratio in more than twice as many patients than by SPE
• Monitor with Hevylite when the monoclonal protein is <10 g/L (e.g. oligosecretory multiple myeloma) – these low levels cannot be measured accurately using electrophoresis

• Detect residual disease - some patients said to have responded well to treatment by electrophoresis methods (Complete Response) were abnormal by Hevylite (see D). The abnormal Hevylite ratio in B-D is produced by immunosuppression of the uninvolved immunoglobulin (IgAλ) rather than an increase in the monoclonal protein IgAκ, highlighting the unique information provided by this test
  
  
• Early detection of relapse allows closer monitoring of patients. A number of publications show disease relapse was indicated by Hevylite some months before detection by IFE and CZE/SPE.